Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

2.750 -0.160 (-5.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62,738
Open 2.860
Bid (Size) 2.610 (8)
Ask (Size) 2.930 (1)
Prev. Close 2.910
Today's Range 2.710 - 2.950
52wk Range 1.910 - 22.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-86.16%
-86.16%
1 Month
+32.85%
+32.85%
3 Month
+16.53%
+16.53%
6 Month
-85.50%
-85.50%
1 Year
-63.72%
-63.72%

More News

Read More
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; Trimble Issues Weak Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
Via Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff
Via Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.